Literature DB >> 390528

Dose response for blood pressure and degree of cardiac beta-blockade with atenolol.

A J Marshall, D W Barritt, S Heaton, J D Harry.   

Abstract

The hypotensive effect of 25 mg, 50 mg, 75 mg, 100 mg and 0 mg of atenolol daily were compared in a double-blind within-patient study. The fall in blood pressure with 25 mg daily was not significantly different than with 100 mg. The dose response curve lies between 0 and 25 mg daily. Cardiac beta-blockade (measured by suppression of exercise tachycardia) was not maximal with 25 mg of atenolol daily. The dose response curves for beta-blockade and the hypotensive effect are not parallel.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 390528      PMCID： PMC2428087          DOI： 10.1136/pgmj.55.646.537

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  5 in total

1.  The effects of miconazole on the ultrastructure of Candida albicans.

Authors:  S de Nollin; M Borgers
Journal:  Proc R Soc Med       Date:  1977

2.  Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration.

Authors:  R G Shanks; S G Carruthers; J G Kelly; D G McDevitt
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Dose response and frequency of administration of atenolol in essential hypertension--once daily treatment with beta-blockade.

Authors:  A J Marshall; D W Barritt; J D Harry
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Clinical studies with atenolol in hypertension.

Authors:  J C Petrie; T A Jeffers; D B Galloway; J Webster
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

5.  Drug complience in hypertensive patients.

Authors:  A Marshall; D W Barritt
Journal:  Br Med J       Date:  1977-05-14
  5 in total
  8 in total

Review 1.  Old antihypertensive agents-diuretics and beta-blockers: do we know how and in whom they lower blood pressure?

Authors:  D A Sica
Journal:  Curr Hypertens Rep       Date:  1999-08       Impact factor: 5.369

Review 2.  Allopathy--the therapeutic legacy.

Authors:  G D Johnston
Journal:  Ir J Med Sci       Date:  1989-01       Impact factor: 1.568

3.  Adverse effects using combined rate-slowing antihypertensive agents.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-06-20       Impact factor: 3.738

4.  Comparison between atenolol and nadolol in essential hypertension at rest and on exercise.

Authors:  R G Wilcox; J R Hampton
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Atenolol and sustained release nifedipine alone and in combination in hypertension. A randomised, double-blind, crossover study.

Authors:  J L Anderton; B D Vallance; N N Stanley; P F Crowe; B Mittra; W H Perks
Journal:  Drugs       Date:  1988       Impact factor: 9.546

6.  A comparative study of atenolol and metoprolol in the treatment of hypertension.

Authors:  S Rasmussen; K Arnung; P C Eskildsen; P E Nielsen
Journal:  Br J Clin Pharmacol       Date:  1981-12       Impact factor: 4.335

7.  A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.

Authors:  T Ishizaki; Y Oyama; T Suganuma; T Sasaki; H Nakaya; T Shibuya; T Sato
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

Review 8.  Quality of life and antihypertensive drug therapy.

Authors:  Joel Handler
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-05       Impact factor: 3.738
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.